May 13, 2013
Bioniche Engages Evercore Partners to Assist in the Divestment of its Animal Health Business

May 8, 2013
Bioniche Life Sciences Inc. Reports Q3, Fiscal 2013 Results

Latest TSX stock price

All prices delayed at least 15 minutes.
Source: TSX Inc.

Latest ASX stock price

All prices delayed at least 20 minutes.
Source: ASX Inc.

Animal Health News Release

Bioniche Receives Authorization to Market Folltropin®-V in Additional EU Countries

21/01/05

BELLEVILLE ON, January 21, 2005 – Bioniche Animal Health, a Division of Bioniche Life Sciences Inc. (TSX:BNC) – a research-based, technology-driven Canadian biopharmaceutical company - today announced that it has been granted authorization to market its Folltropin®-V embryo transfer technology in additional European Union (EU) countries – specifically, in the United Kingdom, the Netherlands, and Spain. Bioniche Life Sciences will continue to seek registrations in other EU countries. The product is already being sold in Ireland.

Folltropin-V acts as a follicle stimulating hormone for cattle. “Folltropin-V already enjoys a significant presence in the world market for superovulatory technology,” noted Martin Warmelink, President of Bioniche Animal Health. “The product has been available in Canada, the United States, Australia, New Zealand, Argentina, Brazil, Ireland, and China for a number of years. Veterinary reproduction specialists in the EU have been eagerly awaiting its arrival on the broader European market.”

Graeme McRae, President & CEO of Bioniche Life Sciences Inc. added, “Folltropin-V is highly regarded by veterinary reproduction specialists worldwide because of its track record of consistent quality and predictable performance.”

Sales of Folltropin-V in the EU will be overseen by Andrew Grant, the new Managing Director of Bioniche Animal Health Europe through the Bioniche Animal Health marketing office located in Galway, Ireland.

Back

Categories:
All Releases
Archived Releases
Animal Health
Corporate
Financial
Human Health
One Health